Management of Dry Mouth Toxicity Following <sup>177</sup>Lu-PSMA-617 Radioligand Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 39522820.
- Also identified by DOI 10.1016/j.prro.2024.10.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with <sup>177</sup>Lu-PSMA-617. Although <sup>177</sup>Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical lumen of the acinar epithelium. Xerostomia resulting from the use of radioligand therapy is common. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 2 dry mouth event after administration of <sup>177</sup>Lu-PSMA-617. The patient was managed with oral hygiene and xerostomia mitigation strategies using oral rinses.
Medical subject headings
- Lutetium
- Dipeptides
- Xerostomia
- Heterocyclic Compounds, 1-Ring
- Prostatic Neoplasms, Castration-Resistant